Tarsus Pharmaceuticals, Inc.
Biopharmaceutical company focused on developing ophthalmic and infectious-disease prevention therapeutics. Maintains marketed ophthalmic therapy for Demodex blepharitis and a clinical pipeline that includes a topical ophthalmic gel for ocular rosacea and an oral systemic formulation for Lyme disease prevention. Activities include formulation R&D, early-stage clinical development, regulatory submissions and commercialization. The company maintains a patent portfolio covering its ophthalmic therapy and disseminates peer-reviewed publications and conference materials on clinical topics.
Industries
Nr. of Employees
large (251-1000)
Tarsus Pharmaceuticals, Inc.
Patents
Method of eradicating ticks that attach to humans using lotilaner formulations
US-12502377-B2
View DetailsPharmaceutical compositions for demodex related blepharitis and eyelid crusting
US-12257263-B2
View DetailsIsoxazoline parasiticide formulations and methods for treating blepharitis
US-12171750-B2
View Details
Method of eradicating ticks that attach to humans using lotilaner formulations
US-12502377-B2
View DetailsPharmaceutical compositions for demodex related blepharitis and eyelid crusting
US-12257263-B2
View DetailsIsoxazoline parasiticide formulations and methods for treating blepharitis
US-12171750-B2
View DetailsProducts
XDEMVY (lotilaner ophthalmic solution) 0.25%
Marketed ophthalmic solution approved for treatment of Demodex blepharitis; indicated as the first FDA-approved therapy in the U.S. for this indication.
TP-04 (topical ophthalmic gel formulation)
Sterile topical ophthalmic gel formulation in clinical development for periorbital and eyelid application to treat ocular rosacea and address Demodex-associated inflammation; under Phase 2 evaluation.
TP-05 (oral systemic formulation)
Oral systemic formulation in development as a non‑vaccine prophylactic intended to kill infected tick vectors prior to transmission of Borrelia bacteria; Phase 1 initiated with Phase 2 planned.
IRX-101 (ocular antiseptic, acquired asset)
Ocular antiseptic asset acquired and added to the company's ophthalmic portfolio.
XDEMVY (lotilaner ophthalmic solution) 0.25%
Marketed ophthalmic solution approved for treatment of Demodex blepharitis; indicated as the first FDA-approved therapy in the U.S. for this indication.
TP-04 (topical ophthalmic gel formulation)
Sterile topical ophthalmic gel formulation in clinical development for periorbital and eyelid application to treat ocular rosacea and address Demodex-associated inflammation; under Phase 2 evaluation.
TP-05 (oral systemic formulation)
Oral systemic formulation in development as a non‑vaccine prophylactic intended to kill infected tick vectors prior to transmission of Borrelia bacteria; Phase 1 initiated with Phase 2 planned.
IRX-101 (ocular antiseptic, acquired asset)
Ocular antiseptic asset acquired and added to the company's ophthalmic portfolio.
Expertise Areas
- Ophthalmic drug development
- Formulation development for topical ophthalmic and oral small-molecule products
- Early-stage clinical development (Phase 1–2)
- Regulatory submissions and FDA approval processes
Key Technologies
- Topical ophthalmic gel and solution formulations
- Oral systemic small-molecule formulation platforms
- Small molecules targeting GABA-gated chloride channels in ectoparasites
- Phase 1–2 clinical trial protocols and platforms
News & Updates
Index of peer-reviewed articles, observational studies, conference posters and presentations documenting clinical outcomes, disease burden, and other clinical research hosted on the company's publications pages.
Company states it has the first FDA-approved therapy in the U.S. for Demodex blepharitis (marketed ophthalmic lotilaner solution).
Company announced and completed acquisition of Alkeus Pharmaceuticals to expand eye care portfolio.
Index of peer-reviewed articles, observational studies, conference posters and presentations documenting clinical outcomes, disease burden, and other clinical research hosted on the company's publications pages.
Company states it has the first FDA-approved therapy in the U.S. for Demodex blepharitis (marketed ophthalmic lotilaner solution).
Company announced and completed acquisition of Alkeus Pharmaceuticals to expand eye care portfolio.